Enhanced Secretory Leukocyte Protease Inhibitor in Human Immunodeficiency Virus Type 1-Infected Patients

Secretory leukocyte protease inhibitor (SLPI) has been found to possess activity against the human immunodeficiency virus type 1 (HIV-1) in vitro at physiological concentrations. A study was undertaken to evaluate SLPI levels in human saliva and plasma among HIV-positive (HIV(+)) patients with vario...

Celý popis

Podrobná bibliografie

Vydáno v:	Clin Diagn Lab Immunol
Hlavní autoři:	Baqui, A. A. M. A., Meiller, Timothy F., Falkler, William A.
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Microbiology (ASM) 1999
Témata:	Article
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC95780/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10548568/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/cdli.6.6.808-811.1999
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!